BRIEF-I-Mab Announces Multiple Clinical Advancements Of Its Differentiated CD73 Antibody Uliledlimab In China And The U.S.

Feb 5 (Reuters) - I-Mab IMAB.O:

• I-MAB ANNOUNCES MULTIPLE CLINICAL ADVANCEMENTS OF ITS DIFFERENTIATED CD73 ANTIBODY ULILEDLIMAB IN CHINA AND THE U.S.

• I-MAB - TOPLINE RESULTS FROM U.S. PHASE 1 STUDY DEMONSTRATE SAFETY AND CLINICAL ACTIVITY

• I-MAB - IN CHINA, I-MAB IS ADVANCING PHASE 1/2 DOSE ESCALATION AND COHORT EXPANSION STUDY OF ULILEDLIMAB

Source text for Eikon: ID:nPn1mk5Fpa

Further company coverage: IMAB.O

((Reuters.Briefs@thomsonreuters.com;))